Skip to main content

LCD L38233: Micro-Invasive Glaucoma Surgery (MIGS)

LCD L38233, Micro-Invasive Glaucoma Surgery (MIGS), is the Local Coverage Determination that First Coast Service Options, Inc. applies to claims from 1 state plus 2 territories (FL, PR, VI), effective 2019-12-30. The policy text runs 1,117 words, and its billing and coding article A56647 lists 48 ICD-10-CM codes that support medical necessity for 7 procedure codes. 6 other contractor versions share this title, so the criteria depend on where the service is furnished. Counting every linked billing and coding article, this one lists 48 covered ICD-10-CM codes: the same total as L38223 (Novitas Solutions, Inc., 48 codes, revised 2019-12-30) and 4 fewer codes than L37244 (Wellpoint Federal, 52 codes, revised 2026-04-01).

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Contractor
First Coast Service Options, Inc.
States and territories
3
FL PR VI
Revision effective
2019-12-30
Original effective
2019-12-30
Policy text
1,117 words
Covered ICD-10 codes (articles)
48

Where this LCD applies

Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.

Contracts that apply LCD L38233
ContractContractorTypeStates
09101First Coast Service Options, Inc.A and B MACFL
09201First Coast Service Options, Inc.A and B MACPR VI
09102First Coast Service Options, Inc.A and B MACFL
09202First Coast Service Options, Inc.A and B MACPR
09302First Coast Service Options, Inc.A and B MACVI

Billing and coding article A56647: diagnoses and procedure codes

Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A56647 (Billing and Coding: Micro-Invasive Glaucoma Surgery (MIGS)) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.

Coverage is only half of the claim edit: when two of the listed procedure codes are billed on the same date, test the pair against the NCCI edits before relying on both being paid.

A56647: Billing and Coding: Micro-Invasive Glaucoma Surgery (MIGS) (Billing and Coding, effective 2023-10-07)

Covered ICD-10-CM codes
48
2 groups
Non-covered ICD-10-CM codes
0
Procedure codes listed
7
Full article
cms.gov record
First 24 covered ICD-10-CM codes in A56647
ICD-10-CMDescription (FY2027)
H40.1111Primary open-angle glaucoma, right eye, mild stage
H40.1112Primary open-angle glaucoma, right eye, moderate stage
H40.1113Primary open-angle glaucoma, right eye, severe stage
H40.1114Primary open-angle glaucoma, right eye, indeterminate stage
H40.1121Primary open-angle glaucoma, left eye, mild stage
H40.1122Primary open-angle glaucoma, left eye, moderate stage
H40.1123Primary open-angle glaucoma, left eye, severe stage
H40.1124Primary open-angle glaucoma, left eye, indeterminate stage
H40.1131Primary open-angle glaucoma, bilateral, mild stage
H40.1132Primary open-angle glaucoma, bilateral, moderate stage
H40.1133Primary open-angle glaucoma, bilateral, severe stage
H40.1134Primary open-angle glaucoma, bilateral, indeterminate stage
H40.1211Low-tension glaucoma, right eye, mild stage
H40.1212Low-tension glaucoma, right eye, moderate stage
H40.1213Low-tension glaucoma, right eye, severe stage
H40.1214Low-tension glaucoma, right eye, indeterminate stage
H40.1221Low-tension glaucoma, left eye, mild stage
H40.1222Low-tension glaucoma, left eye, moderate stage
H40.1223Low-tension glaucoma, left eye, severe stage
H40.1224Low-tension glaucoma, left eye, indeterminate stage
H40.1231Low-tension glaucoma, bilateral, mild stage
H40.1232Low-tension glaucoma, bilateral, moderate stage
H40.1233Low-tension glaucoma, bilateral, severe stage
H40.1234Low-tension glaucoma, bilateral, indeterminate stage

Procedure codes: 0253T, 0449T, 0450T, 0474T, 0671T, 66989, 66991.

Coverage indications, limitations and medical necessity

History/Background and/or General Information

Primary open-angle glaucoma (POAG) is a chronic, progressive optic neuropathy in adults in which there is a characteristic acquired atrophy of the optic nerve and loss of retinal ganglion cells and their axons. A risk factor associated with POAG is increased intraocular pressure (IOP) due to a buildup of aqueous fluid within the eye which can lead to visual field loss and optic nerve damage, usually without any associated pain or discomfort. The increased IOP is secondary to an imbalance between aqueous fluid secretion and fluid outflow despite an open angle. Although many patients with POAG present with increased IOP, nearly 40% of those with otherwise characteristic POAG may not have elevated IOP measurements.

The goal in POAG is to reduce the IOP to slow the development of optic nerve damage. The IOP can be reduced by medical treatment or surgery, alone or in combination. When the maximum tolerated medical therapy fails to control progression of glaucomatous optic neuropathy, surgical care is considered the next treatment option.

Traditional External Filtration Surgery

IOP should be lowered by improving outflow of eye fluid. This is the mechanism used by traditional glaucoma surgeries, such as trabeculectomy, or tube shunt surgeries with aqueous drainage implants. These procedures are performed from outside the eye, or an ab externo approach. Trabeculectomy uses the patient’s own sclera to create a fistula to the subconjunctival space over the sclera superiorly. Aqueous drainage implants use silicone/plastic tubing and large plates to shunt aqueous to the subconjunctival space in the equatorial region of the eyeball.

Micro-Invasive or Minimally Invasive Glaucoma Surgery (MIGS)

The term MIGS refers to a group of newer surgical procedures that are performed by using an ab interno (from inside the eye) approach via gonioscopic guidance and involve minimal trauma to ocular tissues. In contrast to external filtration surgeries such as trabeculectomy and aqueous tube shunt, these procedures are categorized as internal filtration surgeries. Compared with traditional filtration surgery, MIGS holds the promise of faster recovery time and less severe complications.

Covered Indications

Glaucoma surgical aqueous drainage devices will be considered medically reasonable and necessary when approved by the FDA and used within accordance of the FDA-approved/cleared indications.

• A single insertion per eye of an anterior segment aqueous drainage device(s) without extraocular reservoir, via internal approach into the trabecular meshwork or with creation of intraocular reservoir into the supraciliary space is considered medically reasonable and necessary in conjunction with cataract surgery for the treatment of adults with mild or moderate open-angle glaucoma and a cataract when the individual is currently being treated with an ocular hypotensive medication.

• A single insertion per eye of an aqueous drainage device(s) without extraocular reservoir, via internal approach into the subconjunctival space is considered medically reasonable and necessary as a stand- alone treatment for refractory glaucoma, defined as prior failure of filtering/cilioablative procedure and/or uncontrolled IOP (progressive damage and/or mean diurnal medicated IOP greater than or equal to 20 mm Hg) on maximally tolerated medical therapy (i.e., greater than or equal to 4 classes of topical IOP-lowering medications, or fewer in the case of tolerability or efficacy issues).

Limitations

The following are considered not medically reasonable and necessary:

• Glaucoma drainage devices that do not have FDA approval/clearance and/or devices that have been recalled.

• Glaucoma drainage devices used outside of the FDA approval/clearance.

• Insertion of an anterior segment aqueous drainage device without extraocular reservoir, via internal approach into the suprachoroidal space.

• Additional insertions of anterior segment aqueous drainage device(s) without extraocular reservoir, via internal approach into the trabecular meshwork.

• Additional insertions of aqueous drainage device(s) without extraocular reservoir, via internal approach into the subconjunctival.

• A single insertion of an FDA-approved/cleared anterior segment aqueous drainage device(s) without extraocular reservoir, via internal approach into the trabecular meshwork or with creation of intraocular reservoir via internal approach into the supraciliary space not performed in conjunction with cataract surgery.

• Goniotomy procedure performed in conjunction with the insertion of a glaucoma drainage device. Routine performance of goniotomy with insertion of a glaucoma drainage device may be subject to focused medical review.

• Trabeculectomy procedure performed in conjunction with the insertion of a glaucoma drainage device. Routine performance may be subject to focused medical review.

• Insertion of glaucoma drainage device(s) (i.e., one or two microstents) into the trabecular meshwork or into the supraciliary space are limited to one delivery system per eye when performed in conjunction with cataract surgery and when the medically reasonable and necessary criteria as stated above are met.

• Additional delivery system use for device insertions on one eye is considered not medically reasonable and necessary.

• Insertion of glaucoma drainage device(s) into the subconjunctival space are limited to one insertion per eye per day when the medically reasonable and necessary criteria as stated above are met.

• Additional device insertions are considered not medically reasonable and necessary.

As published in the CMS IOM Publication 100-08, Medicare Program Integrity Manual , Chapter 13, Section 13.5.4, an item or service may be covered by a contractor LCD if it is reasonable and necessary under the Social Security Act Section 1862 (a)(1)(A). Contractors shall determine and describe the circumstances under which the item or service is considered reasonable and necessary.

Provider Qualifications

Services will be considered medically reasonable and necessary only if performed by appropriately trained providers. This training and expertise must have been acquired within the frame work of an accredited residency and/or fellowship program in the applicable specialty/subspecialty or must reflect extensive continued medical education activities. If these skills have been acquired by way of continued medical education, the courses must be comprehensive, offered or sponsored or endorsed by an academic institution in the United States and/or by the applicable specialty /subspecialty society in the United States, and designated by the American Medical Association (AMA) as Category I Credit.

• Provider Specialties

• Insertion of glaucoma drainage devices addressed in this LCD must be performed by a qualified physician (MD or DO) who is a board certified ophthalmologist having completed a residency and/or fellowship program and maintains ongoing certification in ophthalmology.

• In addition, insertion of a substitute standalone drainage device into the subconjunctival space without associated cataract extraction must be performed by an ophthalmologist with experience with trabeculectomy and bleb management.

Notice: Services performed for any given diagnosis must meet all of the indications and limitations stated in this LCD, the general requirements for medical necessity as stated in CMS payment policy manuals, any and all existing CMS national coverage determinations, and all Medicare payment rules.

The redetermination process may be utilized for consideration of services performed outside of the reasonable and necessary requirements in this LCD.

Summary of evidence (opening)

Published pivotal trials for FDA Approved/Cleared Glaucoma Drainage Devices:

• iStent® Study Group

A prospective, randomized, open-label, controlled multicenter clinical trial to assess the safety and efficacy of the iStent trabecular micro-bypass stent (Glaukos Corporation, Laguna Hills, CA) in combination with cataract surgery in subjects with mild to moderate open-angle glaucoma was conducted. 1 A total of 240 eyes with mild to moderate open-angle glaucoma with IOP less than or equal to 24 mmHg controlled on 1 to 3 medications were randomized to undergo cataract surgery with iStent implantation (treatment group) or cataract surgery only (control). The study results met the primary outcome, with 72% of treatment eyes versus 50% of control eyes achieving the criterion (P less than 0.001). At 1 year, IOP in both treatment groups was statistically significantly lower from baseline values. Sixty-six percent of treatment eyes versus 48% of control eyes achieved greater than or equal to 20% IOP reduction without medication (P equal to 0.003). The overall incidence of adverse events was similar between groups with no unanticipated adverse device effects. The authors concluded that pressure reduction on fewer medications was clinically and statistically significantly better 1 year after stent plus cataract surgery versus cataract surgery alone, with an overall safety profile similar to that of cataract surgery alone. TRIAL REGISTRATION: ClinicalTrials.gov NCT00323284.

• iStent® Study Group 2 year follow-up

The contractor cites 41 sources in the bibliography; the full summary and analysis of evidence are in the CMS record.

Dates, lineage and related policies

Original determination effective
2019-12-30
Current revision effective
2019-12-30
MCD version
6

Other related documents: A57740 (Response to Comments).

Using this policy on a claim

Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the First Coast Service Options, Inc. hub lists every other active policy from the same contractor.

The same policy title at other contractors

Contractors often adopt each other's policies and then revise them separately, so the criteria and the diagnosis lists drift apart. The topic comparison lines up every version.

For teams evaluating QuickIntell software

Where QuickIntell fits with this policy

If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

What does LCD L38233 cover?

Primary open-angle glaucoma (POAG) is a chronic, progressive optic neuropathy in adults in which there is a characteristic acquired atrophy of the optic nerve and loss of retinal ganglion cells and their axons. A risk factor associated with POAG is increased intraocular pressure (IOP) due to a buildup of aqueous fluid within the eye which can lead to visual field loss and optic nerve damage, usually without any… The full 1,117-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.

Which states does LCD L38233 apply to?

First Coast Service Options, Inc. applies it to Medicare claims in 1 state plus 2 territories: FL, PR, VI. It binds only that contractor; 6 other contractor versions of this title govern other jurisdictions, and elsewhere the same service is judged under the local contractor's own policy or, where none exists, claim by claim.

Which diagnosis codes support medical necessity under LCD L38233?

The companion billing and coding article A56647 lists 48 ICD-10-CM codes in 2 groups that support medical necessity; the first 24 appear on this page, where the complete list opens by group with the contractor's group instructions.

How do I appeal a denial under LCD L38233?

A denial under LCD L38233 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A56647's 48 covered diagnosis codes, then file a redetermination with First Coast Service Options, Inc. within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.